Stanford researchers have developed a method to overcome the packaging capacity limitation of adeno-associated virus (AAV) Vector CRISPR/Cas9 systems to help treat genetic diseases for which the cargo is larger than 4.7kb.
Stanford researchers have developed a new gene editing approach that enables red blood cell-specific gene expression for the treatment of enzyme deficiencies.